SCHEMBL7089403

SCHEMBL7089403

COc1ccc(C(=O)C(=O)c2cccc(-c3cc(C)cs3)c2-c2ccccc2)cc1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.45
CES2 O00748 2/20 0.41
CES1 P23141 2/20 0.41
TNFRSF1A P19438 3/20 0.40
FABP3 P05413 1/20 0.37
FABP4 P15090 1/20 0.37
FABP5 Q01469 1/20 0.37
TAS1R3 Q7RTX0 2/20 0.36
TAS1R1 Q7RTX1 2/20 0.36
ALDH1A1 P00352 3/20 0.36
MAPT P10636 3/20 0.36
KDM4E B2RXH2 2/20 0.36
HPGD P15428 2/20 0.36
HTT P42858 2/20 0.36
GAA P10253 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CNR2 P34972 1/20 0.35
DHODH Q02127 1/20 0.35
LMNA P02545 2/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7085577 0.93 CES2 (0.49) CES2CES1TNFRSF1AFABP3FABP4
SCHEMBL7091527 0.88 TNFRSF1A (0.36) ADORA3TNFRSF1AALDH1A1KDM4EHPGD
SCHEMBL7090554 0.83 NPSR1 (0.37) CES2CES1FABP4ALDH1A1MAPT
SCHEMBL7090550 0.82 AKR1C3 (0.37) ADORA3TNFRSF1AFABP3FABP4FABP5
SCHEMBL7133865 0.81 RAB9A (0.46) CES2CES1ALDH1A1MAPTKDM4E
SCHEMBL7493557 0.78 PTGS2 (0.49) ADORA3CES2CES1
SCHEMBL7085135 0.77 TNF (0.39) TNFRSF1AFABP3FABP4FABP5ALDH1A1
SCHEMBL7090216 0.73 CTSA (0.36) TNFRSF1AHTTCNR2KMT2ATUBB4A
SCHEMBL7088052 0.71 RXFP1 (0.35) CES2CES1ALDH1A1MAPTKDM4E
SCHEMBL7091319 0.70 TTR (0.34) FABP3FABP4FABP5MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2003-03-13 US disclosed
US-6426360-B1 ANTIARTHRITIC AGENTS G D SEARLE & CO. 2002-07-30 US disclosed
WO-1996003387-A1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation AHR, HACL2, IRAK2 ADORA3 1011/4885CES2 984/4885CES1 374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.